Small Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
176
InflaRx
IFRX
$256M
| $256M | $1.74 | 0.58% |
|
|
NAGE
177
Niagen Bioscience
NAGE
$256M
| $256M | $3.21 | 0.63% |
|
|
VRXA
178
Veraxa Biotech AG
VRXA
$255M
| $255M | $1.80 | 3.23% |
|
|
TTRX
179
Turn Therapeutics
TTRX
$254M
| $254M | $8.54 | 9.92% |
|
|
IRD
180
Opus Genetics
IRD
$254M
| $254M | $3.08 | 5.48% |
|
Small Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 180 small cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $250M and $2B — worth a combined $157B.
The largest by market cap are UroGen Pharma (URGN) at $2B, Mesoblast (MESO) at $1.99B and Palvella Therapeutics (PVLA) at $1.98B.
Among institutional investors, Aktis Oncology (AKTS) drew the most net new fund positions in Q1 2026: 69 funds opened new positions.
- Combined market cap: $157B across 180 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: UroGen Pharma (URGN), $2B market cap.
- Most net new fund positions in Q1 2026: Aktis Oncology (AKTS), +69 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.